Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 235.2 Million INR | -10.23% |
| 2022 | 262 Million INR | 41.09% |
| 2021 | 185.7 Million INR | -6.07% |
| 2020 | 197.7 Million INR | 55.55% |
| 2019 | 127.1 Million INR | 1825.76% |
| 2018 | 6.6 Million INR | -34.65% |
| 2017 | 10.1 Million INR | -2.88% |
| 2016 | 10.4 Million INR | -93.01% |
| 2015 | 148.7 Million INR | -55.28% |
| 2014 | 332.5 Million INR | -36.42% |
| 2013 | 523 Million INR | -28.68% |
| 2012 | 733.3 Million INR | -3.63% |
| 2011 | 760.89 Million INR | -60.09% |
| 2010 | 1.9 Billion INR | -16.38% |
| 2009 | 2.27 Billion INR | -8.89% |
| 2008 | 2.5 Billion INR | 44.18% |
| 2007 | 1.73 Billion INR | 49.13% |
| 2006 | 1.16 Billion INR | 18.3% |
| 2005 | 983.65 Million INR | 1.47% |
| 2004 | 969.42 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 0.0% |
| 2024 Q2 | - INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 235.2 Million INR | -10.23% |
| 2023 Q4 | 235.2 Million INR | 0.0% |
| 2023 Q2 | 224.7 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 221.9 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 262 Million INR | 41.09% |
| 2022 Q4 | 262 Million INR | 0.0% |
| 2021 Q4 | 185.7 Million INR | 0.0% |
| 2021 FY | 185.7 Million INR | -6.07% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 181.7 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 197.7 Million INR | 0.0% |
| 2020 FY | 197.7 Million INR | 55.55% |
| 2020 Q2 | 118.7 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 FY | 127.1 Million INR | 1825.76% |
| 2019 Q4 | 127.1 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 355 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 6.7 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 6.6 Million INR | -34.65% |
| 2018 Q4 | 6.6 Million INR | 0.0% |
| 2017 FY | 10.1 Million INR | -2.88% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 10.3 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 10.1 Million INR | 0.0% |
| 2016 Q4 | 10.4 Million INR | 0.0% |
| 2016 FY | 10.4 Million INR | -93.01% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 14.9 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 148.7 Million INR | -55.28% |
| 2015 Q4 | 148.7 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 241.6 Million INR | 0.0% |
| 2014 FY | 332.5 Million INR | -36.42% |
| 2014 Q4 | 332.5 Million INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 523 Million INR | -28.68% |
| 2012 FY | 733.3 Million INR | -3.63% |
| 2011 FY | 760.89 Million INR | -60.09% |
| 2010 FY | 1.9 Billion INR | -16.38% |
| 2009 FY | 2.27 Billion INR | -8.89% |
| 2008 FY | 2.5 Billion INR | 44.18% |
| 2007 FY | 1.73 Billion INR | 49.13% |
| 2006 FY | 1.16 Billion INR | 18.3% |
| 2005 FY | 983.65 Million INR | 1.47% |
| 2004 FY | 969.42 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 62.595% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 98.898% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -59.339% |
| Granules India Limited | 689.71 Million INR | 65.899% |
| Indoco Remedies Limited | 3.51 Billion INR | 93.313% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Alkem Laboratories Limited | 400 Million INR | 41.2% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -6497.475% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -744.949% |
| Bajaj HealthCare Limited | 650.34 Million INR | 63.835% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 33.918% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 96.073% |
| Eris Lifesciences Limited | 6.54 Billion INR | 96.406% |
| FDC Limited | 2.46 Million INR | -9437.713% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 84.495% |
| Gufic Biosciences Limited | 1.53 Billion INR | 84.724% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -110.704% |
| Ipca Laboratories Limited | 5.8 Billion INR | 95.948% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -211.235% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 87.183% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 97.266% |
| Lupin Limited | 1.55 Billion INR | 84.853% |
| Mankind Pharma Limited | 248.67 Million INR | 5.419% |
| Medicamen Biotech Limited | 12.55 Million INR | -1773.357% |
| Medico Remedies Limited | 8.67 Million INR | -2612.177% |
| Megasoft Limited | 1.35 Billion INR | 82.669% |
| NATCO Pharma Limited | 53 Million INR | -343.774% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.053% |
| RPG Life Sciences Limited | -30.3 Million INR | 876.238% |
| Sigachi Industries Limited | 265.79 Million INR | 11.512% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -1668.421% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -10.757% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 19394.504% |
| Unichem Laboratories Limited | 382.22 Million INR | 38.465% |
| Wanbury Limited | 820 Million INR | 71.317% |
| Windlas Biotech Limited | 20.18 Million INR | -1065.51% |
| ZIM Laboratories Limited | 356 Million INR | 33.934% |
| Zydus Lifesciences Limited | 251 Million INR | 6.295% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -120.638% |
| Divi's Laboratories Limited | 20 Million INR | -1076.0% |
| Hester Biosciences Limited | 1.81 Billion INR | 87.061% |
| Procter & Gamble Health Limited | 68.8 Million INR | -241.86% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -1583.849% |
| Bal Pharma Limited | 363.82 Million INR | 35.353% |
| Strides Pharma Science Limited | 6.71 Billion INR | 96.497% |
| Venus Remedies Limited | 386.8 Million INR | 39.193% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -58700.0% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 83.237% |
| Shilpa Medicare Limited | 5.6 Billion INR | 95.801% |
| Aarti Drugs Limited | 2.75 Billion INR | 91.458% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 97.67% |
| Valiant Laboratories Limited | 746.63 Million INR | 68.498% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 0.508% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 77.776% |
| Themis Medicare Limited | 267.74 Million INR | 12.154% |
| Hikal Limited | 4.22 Billion INR | 94.438% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 98.534% |
| Sequent Scientific Limited | 1.42 Billion INR | 83.52% |
| Novartis India Limited | 50.7 Million INR | -363.905% |
| Wockhardt Limited | 8.91 Billion INR | 97.36% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.257% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 47.641% |
| Morepen Laboratories Limited | 33.64 Million INR | -599.168% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -76.126% |